Table 1.
Clinical and laboratory characteristics of 40 patients with IBD
| Characteristic | IBD |
|---|---|
| Total (CD/UC), n | 40 (22/18) |
| Sex, male/female, n | 28/12 |
| Age (mean ± SD), years | 33.2±14.6 |
| Disease activitya | |
| Grade 1 (remission) | 17 |
| Grade 2 (mild) | 15 |
| Grade 3 (moderate) | 4 |
| Grade 4 (severe) | 1 |
| NA | 3 |
| Medication | |
| 5-ASA, n (%) | 36 (90) |
| Azathioprine, n (%) | 16 (40) |
| Laboratory variables (mean ± SD) | |
| Leukocyte count, cells/µL | 6,903±2,370 |
| Lymphocyte count, cells/µL | 1,642±906.1 |
| Hemoglobin level, g/dL | 12.7±2.38 |
| Neutrophil count, cells/µL | 14,251±21,933 |
| Platelet count, ×103 cells/µL | 283.4±120.6 |
| Total protein level, g/dL | 5.93±7.946 |
| Albumin, g/dL | 5.03±1.50 |
| Creatinine, mg/dL | 4.12±13.96 |
| CRP level, mg/dL | 2.61±4.00 |
| ESR level, mm/h | 35.6±22.31 |
IBD, inflammatory bowel disease; CD, Crohn's disease; UC, ulcerative colitis; NA, not available; 5-ASA, 5-acetylsalicylic acid; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate.
a
Disease activity of Crohn's disease and ulcerative colitis was based on Crohn's Disease Activity Index (CDAI) and Mayo Clinical Index (MCI) for Assessment of Ulcerative Colitis Activity, respectively: grade 1, remission (CDAI ≥150, MCI ≤2); grade 2, mild (150≤ CDAI ≤220, 3≤ MCI ≤5); grade 3, moderate (220< CDAI ≤ 450, 6≤ MCI <10); and grade 4, severe (CDAI >450, MCI ≥10).